Major Events - Jinye International Group (08549) plans to issue 100 million shares from September 30 to October 6 [1] - Zhida Technology (02650) intends to globally issue 5.9789 million shares, expecting to list on October 10 [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval for SYH2070 injection (double-stranded small interfering RNA drug) in China [1] - Mixue Group (02097) plans to invest in a fresh beer product company to seize opportunities in the fresh beer industry [1] - Shangshan Gold (01939) proposes a placement at a discount of approximately 19.88%, aiming to raise about HKD 245.8 million [1] - GC Construction (01489) sees a change in controlling interest with a buyout offer at a discount of about 45.91%, resuming trading on October 2 [1] - Times Financial Services Group (00510) major shareholder plans to sell some shares, resuming trading on October 2 [1] - Huajian Medical (01931) confidentially submitted an F-1 registration statement for a dual listing in the U.S. [1] - Ding Shi Capital (00804) intends to acquire 100% equity of a distressed asset disposal business, actively entering the distressed asset market [1] - Chuangmeng Tiandi (01119) plans to issue a total of 236 million shares [1] - Zhaogang Group-W (06676) intends to conduct a share buyback [1] - Daren International (01957) is exploring the possibility of acquiring up to 100 bitcoins [1] - Sihuan Pharmaceutical (00460) received approval from the National Medical Products Administration for its self-developed L-carnosine composite solution water light needle "Frozen Beauty" [1] Bonds and Notes - Minmetals Resources (01208) plans to issue USD 500 million zero-coupon convertible bonds maturing in 2030 [2] Share Buybacks - Tencent Holdings (00700) repurchased approximately 832,000 shares for about HKD 551 million on September 30 [2] - Midea Group (00300) spent approximately CNY 146 million to repurchase 2.0015 million A-shares on September 30 [2] - Anta Sports (02020) repurchased approximately 1.000 million shares for about HKD 99.87 million on September 30 [2] - SF Holding (06936) repurchased approximately 937,600 A-shares for about CNY 37.78 million on September 30 [2] - HSBC Holdings (00005) repurchased approximately 2.1133 million shares for about GBP 22.07 million on September 29 [2] Operating Performance - BYD Company (01211) reported approximately 3.2601 million new energy vehicle sales in the first nine months, a year-on-year increase of 18.64% [2] - Geely Automobile (00175) reported total vehicle sales of 273,100 units in September, a year-on-year increase of approximately 35% [2] - Great Wall Motors (02333) reported total vehicle sales of approximately 133,600 units in September, a year-on-year increase of 23.29% [2] - NIO Inc. (09866) delivered 34,749 vehicles in September, setting a new monthly record with a year-on-year increase of 64.1% [2] - Li Auto (02015) delivered 33,951 new vehicles in September [2]

Core Insights - Vitamin B12, also known as cobalamin, is essential for human health, playing a critical role in nerve function and preventing pernicious anemia. It is used in the treatment of various diseases such as cerebral hemorrhage, Alzheimer's disease, and acute myelitis. The market demand for Vitamin B12 supplements is increasing due to rising health awareness among consumers. The market size of the cobalamin industry in China is projected to reach 1.4 billion yuan in 2024, representing a year-on-year growth of 6% [1][10]. Industry Overview - Cobalamin, or Vitamin B12, is the only vitamin that contains a metal element. It is a red crystalline powder that is water-soluble and plays multiple indispensable roles in the human body, including maintaining a healthy nervous system and promoting red blood cell production [3][10]. - The primary sources of Vitamin B12 are animal products, with some plant sources like soybeans containing lower amounts. The vitamin is crucial for protein and amino acid synthesis, especially in infants [3]. Market Dynamics - China is a major supplier of Vitamin B12 globally, with significant export volumes. The export quantity of unblended Vitamin B12 and its derivatives is expected to grow from 355.08 tons in 2020 to 498.08 tons by 2024 [10]. - The competition in the cobalamin market is intensifying due to limited market size and high domestic production capacity. Major players include Hebei Huaron, Yuxing Bio, Ningxia Jinyi, and Jiutian Pharmaceutical [10][11]. Production Methods - The cobalamin industry primarily utilizes microbial fermentation methods for production, as chemical synthesis is complex and costly. The fermentation process mainly involves anaerobic fermentation using Propionibacterium and aerobic fermentation using Pseudomonas [8]. Industry Trends - The cobalamin industry is expected to see continuous technological innovation, focusing on refining extraction methods and enhancing product stability. The use of biotechnological advancements will likely lead to higher activity and lower impurity levels in cobalamin products [12]. - There is a trend towards high-end and diversified product offerings to meet varying consumer needs, including specialized products for anemia treatment and a wider range of dosage forms [13]. - The industry is moving towards environmentally sustainable practices, including green sourcing of raw materials and energy-efficient extraction processes [14].

格隆汇9月30日丨石药集团(01093.HK)公告，于2025年9月30日，公司间接非全资附属公司石药创新董事 会已批准于联交所主板的H股建议上市。预期紧随H股建议上市完成后，石药创新将仍为公司间接附属 公司。现时预期H股建议上市将涉及透过石药创新新H股于联交所主板首次公开发售进行提呈发售以供 认购，占紧随H股建议上市完成后石药创新经扩大已发行股本不超过10%(假设超额配股权未获行使)。 ...

Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group, has announced the approval of a proposed listing of its indirect non-wholly owned subsidiary, Shijiazhuang Innovation, on the Hong Kong Stock Exchange (HKEX) main board, expected to be completed by September 30, 2025 [1] Summary by Relevant Sections - **Proposed Listing**: The board of Shijiazhuang Innovation has approved the proposal for H-share listing on the HKEX [1] - **Ownership Impact**: Following the completion of the H-share listing, the company's ownership percentage in Shijiazhuang Innovation is expected to decrease by approximately 8.46%, resulting in the company holding about 66.20% of the subsidiary's equity [1] - **Share Issuance**: The proposed listing includes the issuance of shares and an over-allotment option, which, if fully exercised, will affect the company's equity stake [1]

石药集团(01093)公布，于2025年9月30日，公司间接非全资附属公司石药创新董事会已批准于联交所主 板的H股建议上市。预期紧随H股建议上市完成后，石药创新将仍为公司的间接附属公司。 假设紧随H股建议上市完成后石药创新经扩大已发行股本的10%将获发行及超额配股权获悉数行使，石 药创新根据H股建议上市发行及配发发售股份，将导致公司于石药创新的股权百分比减少约8.46%，而 紧随H股建议上市完成后，公司将持有石药创新约66.20%股权。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 須予披露交易 石藥創新H股建議上市所致之視作出售於石藥創新之股權 H股建議上市 董事會宣佈，於2025年9月30日，本公司間接非全資附屬公司石藥創新董事會已批准於聯 交所主板的H股建議上市。預期緊隨H股建議上市完成後，石藥創新將仍為本公司之間接 附屬公司。 現時預期H股建議上市將涉及透過石藥創新之新H股於聯交所主板首次公開發售進行提呈 發 售 以 供 認 購 ， 佔 緊 隨 H 股 建 議 上 市 完 成 後 石 藥 創 新 之 經 擴 大 已 發 行 股 本 不 超 過 10 % （ 假設超額配股權未獲行使 ）。 上市規則的涵義 石 藥創 新 根 據H 股 建 議 上 市發 行 及 配發 發 售 股份 將 導 致本 公 司 於石 藥 創 新之 股 權 ...

Core Viewpoint - The announcement highlights that the company has received approval from the National Medical Products Administration of China for its self-developed Class 1 chemical new drug SYH2070 injection, a dual-strand small interfering RNA (siRNA) drug, to conduct clinical trials in China [1] Group 1: Product Details - SYH2070 is designed for liver-targeted delivery of siRNA through the conjugation of N-acetylgalactosamine (GalNAc) and aims to target angiopoietin-like protein 3 (ANGPTL3) to effectively lower ANGPTL3 levels [1] - The product utilizes optimized sequences and chemical modifications to achieve a more prolonged gene silencing effect, positioning it as a long-acting siRNA drug suitable for treating hypertriglyceridemia or mixed hyperlipidemia [1] - It has the potential to effectively reduce the risk of elevated residual cholesterol levels [1] Group 2: Clinical Development Value - Preclinical studies indicate that SYH2070 demonstrates superior drug activity and efficacy duration compared to similar siRNA products, showcasing differentiated advantages such as lasting drug effects, good safety profile, and high patient compliance [1] - The product holds significant clinical development value due to its promising characteristics [1]

Core Viewpoint - The approval of SYH2070 injection, a novel siRNA drug developed by the company, marks a significant advancement in targeted therapies for hypertriglyceridemia and mixed dyslipidemia, with potential benefits in reducing residual cholesterol levels [1] Group 1: Product Development - The drug SYH2070 is a chemically modified siRNA that targets ANGPTL3 through subcutaneous administration, utilizing GalNAc for liver-targeted delivery [1] - Preclinical studies indicate that SYH2070 demonstrates superior drug activity and prolonged efficacy compared to similar siRNA products, highlighting its differentiated advantages in terms of sustained drug action and safety [1] Group 2: Clinical Implications - The drug is expected to provide a long-lasting effect in lowering ANGPTL3 levels, which is crucial for treating conditions like hypertriglyceridemia and mixed dyslipidemia [1] - The potential for high patient compliance is noted, which could enhance the drug's market acceptance and therapeutic impact [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration of China for its self-developed chemical Class 1 new drug SYH2070 injection, a double-stranded small interfering RNA (siRNA) drug, to conduct clinical trials in China [1] Group 1: Product Details - SYH2070 is designed for liver-targeted delivery of siRNA through the conjugation of N-acetylgalactosamine (GalNAc) and aims to target angiopoietin-like protein 3 (ANGPTL3) to effectively lower ANGPTL3 levels [1] - The product utilizes optimized sequences and chemical modifications to achieve a more prolonged gene silencing effect, positioning it as a long-acting siRNA drug suitable for treating hypertriglyceridemia or mixed hyperlipidemia [1] - It has the potential to effectively reduce the risk of elevated residual cholesterol levels [1] Group 2: Clinical Development Value - Preclinical studies indicate that SYH2070 demonstrates superior drug activity and efficacy duration compared to similar siRNA products, showcasing differentiated advantages such as sustained drug effects, good safety profile, and high patient compliance [1] - The product holds significant clinical development value due to its promising characteristics [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 佈，本集團自主研發的化學1類新藥SYH2070注射液（ 雙鏈小干擾RNA（「si RNA」）藥物 ）（「該 產品」）已獲得中華人民共和國國家藥品監督管理局批准，可在中國開展臨床試驗。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 SYH2070注射液（雙鏈小干擾RNA藥物）在中國獲臨床試驗批准 香港，2025年9月30日 於 本 公 告 日 期 ， 董 事 會 包 括 執 行 董 事 蔡 東 晨 先 生 、 張 翠 龍 先 生 、 王 振 國 先 生 、 潘 衛 東 先 生、王懷玉先生、李春雷博士、姚兵博士、蔡鑫先生及陳衛平先生；及獨立非執 ...